Dear WB/////
Absolutely.....Nice to see someone gets it..":>)...It would be a total shock if the DIC trial turns out badly...there's simply too much comming in on both the clinical and path-phys sides to support it. LEO looks like its run by some "sharp cookies." Best strat for GTCB is to hunker down, conserve their money and wait for more data. Some here have argued BP and the market do not understand GTCB's business,,,,well maybe they don't,,,,but they do understand money....and DIC is money-est, 2-3bil US. Within 6-9 months or perhaps much sooner, they should be able to ink a very profitable deal re DIC which will bring them in money and allow them to keep the 25million from US H-Atryn sales.
Market Data 
Markets 
